Donor choice for stem cell transplant in high-risk leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether choosing a specific type of donor (young male donor or female who has been pregnant) improves the success of a stem cell transplant for people with high-risk or hard-to-treat acute myeloid leukemia (AML). It uses a combination of drugs to prevent graft-versus-host disease, a common side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-risk acute myeloid leukemia (AML) or AML that did not go into remission after standard treatment.
- You have a suitable stem cell donor: either a young male (under 30) or a female who has been pregnant, and who is a partial HLA match to you.
- You are willing to receive a specific combination of medicines to prevent graft-versus-host disease (ATG and PTCy).
- You are not in the intermediate or low-risk group for AML.
- You do not have active leukemia tumors outside the bone marrow at the time of transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a stem cell transplant from a partially matched family member combined with donor immune cells and targeted drugs for acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to help patients who have few other options.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests whether a stem cell transplant from your matched sibling, combined with specially selected immune cells, can help treat aggressive forms of acute myeloid leukemia (AML, a blood cancer). The goal is to improve outcomes for patients whose leukemia is at high risk of returning.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Hear when a new High Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.